Brought to you by 
Eyevance gets global rights to Nexagon from OcuNexus
22 Apr 2021
Executive Summary
OcuNexus Therapeutics Inc. licensed Eyevance Pharmaceuticals LLC worldwide rights to develop and commercialize its ophthalmic candidate Nexagon topical gel.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eyevance gets global rights to Nexagon from OcuNexus
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice